Quick orientation
Cobenfy (xanomeline and trospium chloride) is an oral fixed-dose combination approved by the US FDA in September 2024 for the treatment of schizophrenia in adults. It is the first medicine in a new pharmacologic class for schizophrenia in more than thirty years and the only FDA-approved antipsychotic that does not depend on dopamine D2 receptor blockade. In Saudi Arabia, Cobenfy is not yet registered with the Saudi Food and Drug Authority (SFDA). For Saudi families and treating psychiatrists who have reached the conclusion that a non-D2 mechanism is the right next step, the lawful route is the SFDA Personal Importation Program (PIP), supported by a US specialty pharmacy procurement chain and named-patient documentation prepared in coordination with the dispensing institution. Reserve Meds coordinates the US sourcing, the documentation kit your physician will need, and the international logistics on the family's behalf, while clinical decisions stay with your treating psychiatrist.
How Cobenfy reaches patients in Saudi Arabia
Cobenfy (xanomeline plus trospium chloride, the first FDA-approved muscarinic-receptor-agonist antipsychotic, FDA-approved September 2024 for schizophrenia in adults; marketed by Bristol Myers Squibb after the Karuna Therapeutics acquisition) is not currently visible on the SFDA registered-drug list at sfda.gov.sa/en/drugs-list as of 2026-05-31. Saudi residents access Cobenfy through Personal Importation of Medicines (SFDA Clearance Permit for Personal Use) under SFDA Document Drug-6567E at sfda.gov.sa Drug-6567E PDF. The Cobenfy-specific clinical justification must document: DSM-5 schizophrenia diagnosis with active or recently active positive symptoms, prior antipsychotic trial history (the value proposition of Cobenfy is the avoidance of dopamine-D2 blockade and the associated metabolic and movement-disorder side effects of D2-blocking antipsychotics, particularly relevant where prior D2 antipsychotics have caused tardive dyskinesia, hyperprolactinaemia, or severe metabolic syndrome), and the prescribing psychiatrist's licensure with the Saudi Commission for Health Specialties. The dosing schedule (50 mg/20 mg twice daily titrating to 125 mg/30 mg twice daily per the FDA label) and ECG and cardiovascular monitoring plan are referenced. The supporting medical report must be dated within 6 months of submission. SFDA processing is same-day to several-working-day.
Where Cobenfy is dispensed in Saudi Arabia
Cobenfy is an oral chronic psychiatry therapy administered outpatient; the dispensing setting is psychiatry tertiary or specialty mental-health services. Saudi tertiary psychiatry nodes include Al-Amal Mental Health Hospital in Riyadh, Jeddah, and Dammam (MOH's flagship mental-health speciality hospital network); King Fahad Medical City (KFMC) Department of Psychiatry in Riyadh at kfmc.med.sa; King Faisal Specialist Hospital and Research Centre (KFSHRC) Department of Psychiatry in Riyadh and Jeddah at kfshrc.edu.sa; King Khalid University Hospital Department of Psychiatry in Riyadh; King Abdulaziz Medical City (KAMC) Department of Psychiatry in Riyadh and Jeddah; and Erada Mental Health Complex (MOH) facilities in Riyadh, Dammam, Jeddah, and other regions. Al-Amal Hospital is the country's largest specialty mental-health centre and runs the largest schizophrenia outpatient clinic load nationally. The dispensing pathway requires the prescribing psychiatrist's institutional pharmacy access; private-practice psychiatrists typically route through a tertiary-hospital pharmacy under chain-of-custody documentation.
What Cobenfy costs in Saudi Arabia
The US reference WAC for Cobenfy is approximately USD 1,800 to USD 2,000 per 30-day supply at maintenance dose per Bristol Myers Squibb published pricing and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual WAC at maintenance dose runs approximately USD 22,000 to USD 24,000. No public SAR benchmark for Cobenfy is observed on the SFDA drugs list or via NUPCO at nupco.com as of 2026-05-31; the drug is not currently SFDA-registered. Do not estimate. Price snapshot: 2026-05-31. The Saudi Riyal is USD-pegged at approximately 3.75 SAR per USD; the peg removes FX volatility. Cost layers: ambient-temperature international logistics into Saudi Arabia (low four-figure USD; Cobenfy is a stable oral combination capsule), SFDA personal-import clearance fees (nominal), the dispensing psychiatry-clinic consultation and surveillance fees (clinical interview, AIMS or similar movement-disorder assessment at the FDA-label intervals), and Reserve Meds concierge fee itemised separately. For Saudi nationals at MOH psychiatry facilities the drug-product cost is typically borne by the institutional channel where the Special Access Programme has been invoked; out-of-pocket exposure is materially lower than for non-citizens.
Funding and access barriers for Cobenfy in Saudi Arabia
Schizophrenia prevalence in Saudi Arabia is consistent with global rates (approximately 0.5 to 1% of the adult population). The historical pharmacological landscape covers first-generation antipsychotics (haloperidol, chlorpromazine), second-generation atypical antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole, clozapine), and long-acting injectables. Cobenfy as a first-in-class muscarinic-agonist antipsychotic has no Saudi-registered equivalent. Public-sector funding: Saudi nationals receive mental-health services at MOH-affiliated facilities (Al-Amal Hospitals, KFMC, KFSHRC psychiatry) without direct charge; NUPCO procurement covers the registered antipsychotic formulary, but Cobenfy is not currently on the NUPCO list. Institutional access via the SFDA Special Access Programme is procedurally available but requires a clinical committee approval based on documented inadequate response to or intolerance of D2-blocking antipsychotics. The Council of Health Insurance Essential Benefits Package covers mental-health services as a mandated category but does not currently extend to Cobenfy. Major Saudi cooperative health insurers (Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Al Rajhi Takaful) typically cover schizophrenia care including registered antipsychotics; named-patient unregistered-drug imports require prior authorisation and tier-specific coverage. KSrelief case-by-case humanitarian programmes do not typically extend to chronic psychiatry maintenance. Out-of-pocket self-pay is the dominant funding source for Cobenfy named-patient imports as of 2026-05-31.
Recent regulatory and access news for Cobenfy
FDA approved Cobenfy (xanomeline-trospium, KarXT) on 26 September 2024 for schizophrenia in adults based on the EMERGENT-2 and EMERGENT-3 phase 3 trials, the first non-D2 mechanism antipsychotic approval in decades; the approval letter is at accessdata.fda.gov/scripts/cder/daf. Bristol Myers Squibb (after the Karuna Therapeutics acquisition completed March 2024) has prioritised global launch including European MAA via EMA; the EMA review is ongoing as of 2026-05-31. BMS has also disclosed phase 3 development of Cobenfy in adjunctive therapy for inadequately controlled schizophrenia and in Alzheimer's disease psychosis. The SFDA News feed at sfda.gov.sa/en/news does not document a Cobenfy submission or registration over the last 12 months. SFDA Drug-6567E remains the operative reference for the patient-led personal-import pathway.
Where Reserve Meds fits in Cobenfy cases
Reserve Meds is a US-based concierge coordinator. We do not replace your psychiatrist, do not replace SFDA, and do not replace your dispensing pharmacy. For a Cobenfy case in the Kingdom, we orchestrate the US specialty pharmacy procurement (Cobenfy moves through the BMS specialty pharmacy channel rather than open wholesale distribution), prepare the documentation kit your physician needs for the SFDA Personal Importation Program, coordinate the international shipment under ambient conditions with full customs documentation, and stay with the case through reorders under a single named coordinator. No prior Reserve Meds Cobenfy case experience is on file as of this page's review date, which is typical for a drug launched in late 2024; standard SFDA named-patient coordination applies, and the operational profile (small molecule, room temperature, oral, no REMS, no cold-chain, no reconstitution) is among the easier in the Reserve Meds matrix to coordinate. The clinical decisions remain with your treating psychiatrist. The regulatory authority remains SFDA. The dispensing remains with the licensed Saudi pharmacy.
Next step
If your family is exploring Cobenfy for an adult relative whose psychiatrist has documented prior-line failure or intolerance on D2 antagonists, the next step is to We will confirm eligibility and case fit within 24 to 48 hours, send a documentation kit to your treating psychiatrist, and align with your institution's import pharmacy or with an SFDA-licensed specialty importer in Riyadh or Jeddah on the SFDA filing.
Reserved for you.